AVRO

Mizuho Securities analyst Uy Ear maintained a Buy rating on Avrobio (AVRO - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $0.78.Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Ocugen, and Satsuma Pharmaceuticals. According to TipRanks, Ear has an average return of 6.5% and a 30.51% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avrobio with a $5.33 average price target, which is a 581.93% upside from current levels. In a report released yesterday, BTIG also upgraded the stock to a Buy with a $4.
https://www.tipranks.com/news/blurbs/avrobio-avro-gets-a-buy-from-mizuho-securities?utm_source=advfn.com&utm_medium=referral